search
Back to results

Tiotropium / Respimat One Year Study in COPD.

Primary Purpose

Pulmonary Disease, Chronic Obstructive

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Respimat
Tiotropium
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female
  2. At least 40 years old
  3. Smoker or ex-smoker
  4. Smoking history > 10 pack-years
  5. Forced Expiratory Volume in 1 Second (FEV1) < 60% predicted

Exclusion Criteria:

  1. Recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure
  2. History of asthma or allergic conditions.
  3. Malignancy requiring treatment within past 5 years
  4. Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis
  5. Known active tuberculosis
  6. Known hypersensitivity to anticholinergic drugs.

Sites / Locations

  • 205.372.01012 Boehringer Ingelheim Investigational Site
  • 205.372.01020 Boehringer Ingelheim Investigational Site
  • 205.372.01062 Boehringer Ingelheim Investigational Site
  • 205.372.01048 Boehringer Ingelheim Investigational Site
  • 205.372.01037 Boehringer Ingelheim Investigational Site
  • 205.372.01058 Boehringer Ingelheim Investigational Site
  • 205.372.01059 Boehringer Ingelheim Investigational Site
  • 205.372.01007 Boehringer Ingelheim Investigational Site
  • 205.372.01034 Boehringer Ingelheim Investigational Site
  • 205.372.01028 Boehringer Ingelheim Investigational Site
  • 205.372.01011 Boehringer Ingelheim Investigational Site
  • 205.372.01066 Boehringer Ingelheim Investigational Site
  • 205.372.01008 Boehringer Ingelheim Investigational Site
  • 205.372.01004 Boehringer Ingelheim Investigational Site
  • 205.372.01060 Boehringer Ingelheim Investigational Site
  • 205.372.01069 Boehringer Ingelheim Investigational Site
  • 205.372.01023 Boehringer Ingelheim Investigational Site
  • 205.372.01053 Boehringer Ingelheim Investigational Site
  • 205.372.01045 Boehringer Ingelheim Investigational Site
  • 205.372.01043 Boehringer Ingelheim Investigational Site
  • 205.372.01061 Boehringer Ingelheim Investigational Site
  • 205.372.01035 Boehringer Ingelheim Investigational Site
  • 205.372.01049 Boehringer Ingelheim Investigational Site
  • 205.372.01015 Boehringer Ingelheim Investigational Site
  • 205.372.01067 Boehringer Ingelheim Investigational Site
  • 205.372.01006 Boehringer Ingelheim Investigational Site
  • 205.372.01013 Boehringer Ingelheim Investigational Site
  • 205.372.01003 Boehringer Ingelheim Investigational Site
  • 205.372.01021 Boehringer Ingelheim Investigational Site
  • 205.372.01014 Boehringer Ingelheim Investigational Site
  • 205.372.01036 Boehringer Ingelheim Investigational Site
  • 205.372.01046 Boehringer Ingelheim Investigational Site
  • 205.372.01024 Boehringer Ingelheim Investigational Site
  • 205.372.01029 Boehringer Ingelheim Investigational Site
  • 205.372.01030 Boehringer Ingelheim Investigational Site
  • 205.372.01026 Boehringer Ingelheim Investigational Site
  • 205.372.01019 Boehringer Ingelheim Investigational Site
  • 205.372.01027 Boehringer Ingelheim Investigational Site
  • 205.372.01038 Boehringer Ingelheim Investigational Site
  • 205.372.01031 Boehringer Ingelheim Investigational Site
  • 205.372.01017 Boehringer Ingelheim Investigational Site
  • 205.372.01041 Boehringer Ingelheim Investigational Site
  • 205.372.01044 Boehringer Ingelheim Investigational Site
  • 205.372.01001 Boehringer Ingelheim Investigational Site
  • 205.372.01063 Boehringer Ingelheim Investigational Site
  • 205.372.01068 Boehringer Ingelheim Investigational Site
  • 205.372.01056 Boehringer Ingelheim Investigational Site
  • 205.372.01039 Boehringer Ingelheim Investigational Site
  • 205.372.01050 Boehringer Ingelheim Investigational Site
  • 205.372.01005 Boehringer Ingelheim Investigational Site
  • 205.372.01018 Boehringer Ingelheim Investigational Site
  • 205.372.01040 Boehringer Ingelheim Investigational Site
  • 205.372.01052 Boehringer Ingelheim Investigational Site
  • 205.372.01022 Boehringer Ingelheim Investigational Site
  • 205.372.01065 Boehringer Ingelheim Investigational Site
  • 205.372.01055 Boehringer Ingelheim Investigational Site
  • 205.372.01064 Boehringer Ingelheim Investigational Site
  • 205.372.61002 Woolcock Institute of Medical Research
  • 205.372.61009 Thoracic & General Physician
  • 205.372.61005 Redcliffe Hospital
  • 205.372.61006 The Investigator Clinic
  • 205.372.61007 The Burnside War Memorial Hospital
  • 205.372.61004 Boehringer Ingelheim Investigational Site
  • 205.372.61010 Ecru
  • 205.372.61008 Geelong Clinical Research Centre
  • 205.372.61001 Emeritus Research
  • 205.372.61003 Sir Charles Gairdner Hospital
  • 205.372.55012 Universidade Federal de Santa Catarina
  • 205.372.55009 Hospital das Clínicas de Goiânia
  • 205.372.55005 Hospital Geral Otávio de Freitas
  • 205.372.55001 INCOR e Hospital das Clínicas da Universidade de São Paulo
  • 205.372.55010 Unidade de Coracao e Pulmao do Dto. de Medicina
  • 205.372.55011 CEDOES - Diagnóstico e Pesquisa
  • 205.372.11007 Heritage Medical Research Building
  • 205.372.11013 Calgary West Medical Centre
  • 205.372.11011 Hermitage Medicentre
  • 205.372.11017 Boehringer Ingelheim Investigational Site
  • 205.372.11020 Wetaskiwin Lung Laboratory
  • 205.372.11010 Dr. Kay Ho
  • 205.372.11018 Pacific Lung Health Centre
  • 205.372.11005 Professional Corp. Respirology
  • 205.372.11009 White Hills Medical Clinic
  • 205.372.11012 West Lincoln Memorial Hospital
  • 205.372.11014 Dr. Robert Luton
  • 205.372.11001 Niagara Clinical Research
  • 205.372.11019 Allergy and Asthma Research Centre
  • 205.372.11003 London Road Diagnostic Clinic and Medical Centre
  • 205.372.11016 London Road Diagnostic Clinic and Medical Centre
  • 205.372.11002 Centenary Respiratory Research Associates
  • 205.372.11006 Clinique de médecine familiale de La Malbaie
  • 205.372.11004 Mount Royal Family Physicians
  • 205.372.11015 Dr. Arun Nayar
  • 205.372.86002 Boehringer Ingelheim Investigational Site
  • 205.372.86003 Boehringer Ingelheim Investigational Site
  • 205.372.86004 Boehringer Ingelheim Investigational Site
  • 205.372.86009 Boehringer Ingelheim Investigational Site
  • 205.372.86008 Boehringer Ingelheim Investigational Site
  • 205.372.86001 Boehringer Ingelheim Investigational Site
  • 205.372.86010 Boehringer Ingelheim Investigational Site
  • 205.372.86011 Boehringer Ingelheim Investigational Site
  • 205.372.86012 Boehringer Ingelheim Investigational Site
  • 205.372.86005 Boehringer Ingelheim Investigational Site
  • 205.372.86006 Boehringer Ingelheim Investigational Site
  • 205.372.86007 Boehringer Ingelheim Investigational Site
  • 205.372.45004 Boehringer Ingelheim Investigational Site
  • 205.372.45005 Boehringer Ingelheim Investigational Site
  • 205.372.45002 Boehringer Ingelheim Investigational Site
  • 205.372.45001 Boehringer Ingelheim Investigational Site
  • 205.372.45003 Boehringer Ingelheim Investigational Site
  • 205.372.45006 Boehringer Ingelheim Investigational Site
  • 205.372.35804 Boehringer Ingelheim Investigational Site
  • 205.372.35802 Boehringer Ingelheim Investigational Site
  • 205.372.35803 Boehringer Ingelheim Investigational Site
  • 205.372.35801 Boehringer Ingelheim Investigational Site
  • 205.372.3318A Clinique du Parc
  • 205.372.3318B Clinique du Parc
  • 205.372.3304A Cabinet Médical
  • 205.372.3301A Hôpital Gabriel Montpied
  • 205.372.3310A Centre Hospitalier
  • 205.372.3314A Cabinet Médical
  • 205.372.3306A Hôpital Ambroise Paré
  • 205.372.3303A Hôpital Notre Dame de Bon Secours
  • 205.372.3303B Hôpital Notre Dame de Bon Secours
  • 205.372.3312A Cabinet Médical
  • 205.372.3312B Cabinet Médical
  • 205.372.3302A Centre Médical Erdre Saint Augustin
  • 205.372.3305A Cabinet Médical
  • 205.372.3305B Cabinet Médical
  • 205.372.3315B Hôpital Caremeau
  • 205.372.3315A Hôpital Caremeau
  • 205.372.3317A Cabinet de Pneumologie
  • 205.372.3320A Polyclinique Les Fleurs
  • 205.372.3320B Polyclinique Les Fleurs
  • 205.372.3316A Clinique les Bleuets
  • 205.372.3316B Clinique les Bleuets
  • 205.372.3319A Institut Arnault Tzanck
  • 205.372.3325A Cabinet Médical
  • 205.372.3321A Centre Hospitalier
  • 205.372.3321C Centre Hospitalier
  • 205.372.3324A Cabinet Médical
  • 205.372.3309A Cabinet médical
  • 205.372.3309B Cabinet médical
  • 205.372.49002 Boehringer Ingelheim Investigational Site
  • 205.372.49004 Boehringer Ingelheim Investigational Site
  • 205.372.49013 Boehringer Ingelheim Investigational Site
  • 205.372.49007 Boehringer Ingelheim Investigational Site
  • 205.372.49008 Boehringer Ingelheim Investigational Site
  • 205.372.49011 Boehringer Ingelheim Investigational Site
  • 205.372.49012 Boehringer Ingelheim Investigational Site
  • 205.372.49006 Boehringer Ingelheim Investigational Site
  • 205.372.49014 Boehringer Ingelheim Investigational Site
  • 205.372.49005 Boehringer Ingelheim Investigational Site
  • 205.372.49009 Boehringer Ingelheim Investigational Site
  • 205.372.49010 Boehringer Ingelheim Investigational Site
  • 205.372.49016 Boehringer Ingelheim Investigational Site
  • 205.372.49015 Boehringer Ingelheim Investigational Site
  • 205.372.49001 Boehringer Ingelheim Investigational Site
  • 205.372.49003 Boehringer Ingelheim Investigational Site
  • 205.372.30001 Boehringer Ingelheim Investigational Site
  • 205.372.30002 Boehringer Ingelheim Investigational Site
  • 205.372.30003 Boehringer Ingelheim Investigational Site
  • 205.372.30013 Boehringer Ingelheim Investigational Site
  • 205.372.30015 Boehringer Ingelheim Investigational Site
  • 205.372.30009 Boehringer Ingelheim Investigational Site
  • 205.372.30007 Boehringer Ingelheim Investigational Site
  • 205.372.30005 Boehringer Ingelheim Investigational Site
  • 205.372.30004 Boehringer Ingelheim Investigational Site
  • 205.372.30011 Boehringer Ingelheim Investigational Site
  • 205.372.30019 Boehringer Ingelheim Investigational Site
  • 205.372.30008 Boehringer Ingelheim Investigational Site
  • 205.372.30006 Boehringer Ingelheim Investigational Site
  • 205.372.30017 Boehringer Ingelheim Investigational Site
  • 205.372.30014 Boehringer Ingelheim Investigational Site
  • 205.372.85203 Boehringer Ingelheim Investigational Site
  • 205.372.85201 Boehringer Ingelheim Investigational Site
  • 205.372.36001 Boehringer Ingelheim Investigational Site
  • 205.372.36002 Boehringer Ingelheim Investigational Site
  • 205.372.36004 Boehringer Ingelheim Investigational Site
  • 205.372.36005 Boehringer Ingelheim Investigational Site
  • 205.372.36006 Boehringer Ingelheim Investigational Site
  • 205.372.36007 Boehringer Ingelheim Investigational Site
  • 205.372.91005 Boehringer Ingelheim Investigational Site
  • 205.372.91016 Boehringer Ingelheim Investigational Site
  • 205.372.91003 Boehringer Ingelheim Investigational Site
  • 205.372.91006 Boehringer Ingelheim Investigational Site
  • 205.372.91017 Boehringer Ingelheim Investigational Site
  • 205.372.91007 Boehringer Ingelheim Investigational Site
  • 205.372.91010 Boehringer Ingelheim Investigational Site
  • 205.372.91002 Boehringer Ingelheim Investigational Site
  • 205.372.91009 Boehringer Ingelheim Investigational Site
  • 205.372.91011 Boehringer Ingelheim Investigational Site
  • 205.372.91012 Boehringer Ingelheim Investigational Site
  • 205.372.91004 Boehringer Ingelheim Investigational Site
  • 205.372.91008 Boehringer Ingelheim Investigational Site
  • 205.372.91015 Boehringer Ingelheim Investigational Site
  • 205.372.91014 Boehringer Ingelheim Investigational Site
  • 205.372.91013 Boehringer Ingelheim Investigational Site
  • 205.372.91001 Boehringer Ingelheim Investigational Site
  • 205.372.35303 Boehringer Ingelheim Investigational Site
  • 205.372.39007 Boehringer Ingelheim Investigational Site
  • 205.372.39012 Boehringer Ingelheim Investigational Site
  • 205.372.39003 Boehringer Ingelheim Investigational Site
  • 205.372.39004 Boehringer Ingelheim Investigational Site
  • 205.372.39005 Boehringer Ingelheim Investigational Site
  • 205.372.39008 Boehringer Ingelheim Investigational Site
  • 205.372.39009 Boehringer Ingelheim Investigational Site
  • 205.372.39001 Boehringer Ingelheim Investigational Site
  • 205.372.39010 Boehringer Ingelheim Investigational Site
  • 205.372.39002 Boehringer Ingelheim Investigational Site
  • 205.372.39011 Boehringer Ingelheim Investigational Site
  • 205.372.39006 Boehringer Ingelheim Investigational Site
  • 205.372.82010 Boehringer Ingelheim Investigational Site
  • 205.372.82005 Boehringer Ingelheim Investigational Site
  • 205.372.82009 Boehringer Ingelheim Investigational Site
  • 205.372.82003 Boehringer Ingelheim Investigational Site
  • 205.372.82008 Boehringer Ingelheim Investigational Site
  • 205.372.82007 Boehringer Ingelheim Investigational Site
  • 205.372.82002 Boehringer Ingelheim Investigational Site
  • 205.372.82001 Boehringer Ingelheim Investigational Site
  • 205.372.82004 Boehringer Ingelheim Investigational Site
  • 205.372.82006 Boehringer Ingelheim Investigational Site
  • 205.372.37001 Boehringer Ingelheim Investigational Site
  • 205.372.37003 Boehringer Ingelheim Investigational Site
  • 205.372.37002 Boehringer Ingelheim Investigational Site
  • 205.372.60007 Boehringer Ingelheim Investigational Site
  • 205.372.60004 Boehringer Ingelheim Investigational Site
  • 205.372.60005 Boehringer Ingelheim Investigational Site
  • 205.372.60006 Boehringer Ingelheim Investigational Site
  • 205.372.60002 Boehringer Ingelheim Investigational Site
  • 205.372.60003 Boehringer Ingelheim Investigational Site
  • 205.372.60001 Boehringer Ingelheim Investigational Site
  • 205.372.52018 Hospital Universitario de Chihuahua
  • 205.372.52017 Instituto Nacional de Enfermedades Respiratorias (INER)
  • 205.372.52013 Sanatorio Henri Dunant
  • 205.372.52009 Hospital Civil Antiguo
  • 205.372.52005 Hospital Civil Nuevo de Guadalajara
  • 205.372.52001 Hospital General del Estado de Sonora
  • 205.372.52014 Hospital Angeles de las Lomas
  • 205.372.52004 Clínica de Mérida
  • 205.372.52016 Hospital General de Mexicali
  • 205.372.52002 Unidad de Investigación clínica en Medicina
  • 205.372.52006 Hospital Universitario
  • 205.372.52010 Hospital General Agustin O´Haran
  • 205.372.52012 Hospital de Nuestra Señora de la Salud
  • 205.372.52003 Hospital "Angel Leaño"
  • 205.372.31009 Boehringer Ingelheim Investigational Site
  • 205.372.31006 Boehringer Ingelheim Investigational Site
  • 205.372.31001 Boehringer Ingelheim Investigational Site
  • 205.372.31011 Boehringer Ingelheim Investigational Site
  • 205.372.31007 Boehringer Ingelheim Investigational Site
  • 205.372.31004 Boehringer Ingelheim Investigational Site
  • 205.372.31003 Boehringer Ingelheim Investigational Site
  • 205.372.31012 Boehringer Ingelheim Investigational Site
  • 205.372.31002 Boehringer Ingelheim Investigational Site
  • 205.372.31008 Boehringer Ingelheim Investigational Site
  • 205.372.31005 Boehringer Ingelheim Investigational Site
  • 205.372.47001 Boehringer Ingelheim Investigational Site
  • 205.372.47003 Boehringer Ingelheim Investigational Site
  • 205.372.47002 Boehringer Ingelheim Investigational Site
  • 205.372.35102 Hospital Fernando Fonseca
  • 205.372.35101 Hospital Pulido Valente
  • 205.372.35104 Hospital de Santa Marta
  • 205.372.35103 Hospital de São João
  • 205.372.35105 Centro Hospitalar do Alto Minho, Estrada de Santa Luzia
  • 205.372.65001 Boehringer Ingelheim Investigational Site
  • 205.372.65003 Boehringer Ingelheim Investigational Site
  • 205.372.65005 Boehringer Ingelheim Investigational Site
  • 205.372.42102 Boehringer Ingelheim Investigational Site
  • 205.372.42103 Boehringer Ingelheim Investigational Site
  • 205.372.27002 Boehringer Ingelheim Investigational Site
  • 205.372.27001 Boehringer Ingelheim Investigational Site
  • 205.372.27004 Boehringer Ingelheim Investigational Site
  • 205.372.27008 Boehringer Ingelheim Investigational Site
  • 205.372.27006 Boehringer Ingelheim Investigational Site
  • 205.372.27003 Boehringer Ingelheim Investigational Site
  • 205.372.27005 Boehringer Ingelheim Investigational Site
  • 205.372.27007 Boehringer Ingelheim Investigational Site
  • 205.372.34005 Hospital San Pedro de Alcántara
  • 205.372.34004 Hospital Gregorio Marañón
  • 205.372.34006 Hospital 12 de octubre
  • 205.372.34001 Hospital Mutua Terrassa
  • 205.372.34002 Hospital Universitario Dr. Peset
  • 205.372.46001 Björknäs Vårdcentral
  • 205.372.46004 Näsets läkargrupp
  • 205.372.46005 Lungmedicinska kliniken
  • 205.372.46006 Lungmedicinska Kliniken
  • 205.372.46002 Alnö Vårdcentral
  • 205.372.41002 Boehringer Ingelheim Investigational Site
  • 205.372.41003 Boehringer Ingelheim Investigational Site
  • 205.372.41001 Boehringer Ingelheim Investigational Site
  • 205.372.88607 Kaohsiung Medical University Hospital
  • 205.372.88606 National Cheng Kung University Hospital
  • 205.372.88601 National Taiwan University Hospital
  • 205.372.88602 Taipei Veterans General Hospital
  • 205.372.88603 Mackay Memorial Hospital
  • 205.372.88604 Tri-Service General Hospital
  • 205.372.88608 Boehringer Ingelheim Investigational Site
  • 205.372.88609 Boehringer Ingelheim Investigational Site
  • 205.372.88605 Chang Gung Memorial Hosp-Linkou
  • 205.372.90006 Gazi Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.
  • 205.372.90007 Atatürk Gög. Hastaliklari ve Cerrahisi Egitim Hastanesi
  • 205.372.90003 Uludag Universitesi Tip Fakultesi Gogus Hastaliklari
  • 205.372.90009 Trakya Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.
  • 205.372.90004 Dr. Lütfi Kirdar Egitim ve Arastirma Hastanesi
  • 205.372.90005 Istanbul Universitesi Cerrahpasa Tip Fakultesi
  • 205.372.90001 Izmir Tepecik Gogus Hastaliklari ve Gogus Cerrahisi Hast.
  • 205.372.90008 Erciyes Universitesi Tip Fakultesi
  • 205.372.90010 Selcuk Universitesi Tip Fakultesi
  • 205.372.90002 19 Mayis Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D
  • 205.372.44027 Boehringer Ingelheim Investigational Site
  • 205.372.44022 Boehringer Ingelheim Investigational Site
  • 205.372.44002 Boehringer Ingelheim Investigational Site
  • 205.372.44023 Boehringer Ingelheim Investigational Site
  • 205.372.44014 Boehringer Ingelheim Investigational Site
  • 205.372.44009 Boehringer Ingelheim Investigational Site
  • 205.372.44011 Boehringer Ingelheim Investigational Site
  • 205.372.44003 Boehringer Ingelheim Investigational Site
  • 205.372.44026 Boehringer Ingelheim Investigational Site
  • 205.372.44013 Boehringer Ingelheim Investigational Site
  • 205.372.44016 Boehringer Ingelheim Investigational Site
  • 205.372.44020 Boehringer Ingelheim Investigational Site
  • 205.372.44024 Boehringer Ingelheim Investigational Site
  • 205.372.44001 Boehringer Ingelheim Investigational Site
  • 205.372.44018 Boehringer Ingelheim Investigational Site
  • 205.372.44021 Boehringer Ingelheim Investigational Site
  • 205.372.44007 Boehringer Ingelheim Investigational Site
  • 205.372.44010 Boehringer Ingelheim Investigational Site
  • 205.372.44005 Boehringer Ingelheim Investigational Site
  • 205.372.44015 Boehringer Ingelheim Investigational Site
  • 205.372.44006 Boehringer Ingelheim Investigational Site
  • 205.372.44008 Boehringer Ingelheim Investigational Site
  • 205.372.44012 Boehringer Ingelheim Investigational Site
  • 205.372.44028 Boehringer Ingelheim Investigational Site
  • 205.372.44019 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Tiotropium

Placebo

Arm Description

Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)

Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)

Outcomes

Primary Outcome Measures

Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337
Trough FEV1 is defined as the FEV1 measured at the -10 min time point at the end of the dosing interval (24 h post drug administration).
Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Time to first COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation.

Secondary Outcome Measures

Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29
Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 169
Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.
Number of COPD Exacerbations Per Patient - Exposure Adjusted
Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. number of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)
Number of COPD Exacerbations Per Patient - naïve Estimate
Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)
Number of Patients With at Least One COPD Exacerbation
Number of patients with at least one COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)
Time to First Hospitalisation for COPD Exacerbation
Time to first hospitalisation for COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation
Number of Hospitalisations for COPD Exacerbations Per Patient - Exposure Adjusted
Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. no. of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)
Number of Hospitalisations for COPD Exacerbations Per Patient - naïve Estimate
Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)
Number of Patients With at Least One Hospitalisation for a COPD Exacerbation
Number of patients with at least one hospitalisation for a COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 337
The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 169
The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 337
The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 169
The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 29
Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.
Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 169
Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.
Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 337
Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.
Marked Changes From Baseline in Vital Signs at End of Treatment
Marked changes from baseline in vital signs (diastolic and systolic blood pressure (DBP and SBP) and pulse rate (PR)) at end of treatment. SBP - Increase means SBP >150 mmHg and an increase above baseline of >25 mmHg. SBP - Decrease means SBP <100 mmHg and a decrease below baseline of >10 mmHg. DBP - Increase means DBP >90 mmHg and an increase above baseline of >10 mmHg. DBP - Decrease means DBP <60 mmHg and a decrease below baseline of >10 mmHg. PR - Increase means PR >100 bpm and an increase above baseline of >10 bpm. PR - Decrease means PR <60 bpm and a decrease below baseline of >10 bpm.
Clinically Relevant Findings in Physical Examination and ECG
Clinically relevant findings in Physical Examination and ECG at end of treatment

Full Information

First Posted
October 11, 2006
Last Updated
May 7, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00387088
Brief Title
Tiotropium / Respimat One Year Study in COPD.
Official Title
Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD
Study Type
Interventional

2. Study Status

Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
September 2006 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Disease, Chronic Obstructive

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Enrollment
3991 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tiotropium
Arm Type
Other
Arm Description
Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
Arm Title
Placebo
Arm Type
Other
Arm Description
Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
Intervention Type
Device
Intervention Name(s)
Respimat
Intervention Type
Drug
Intervention Name(s)
Tiotropium
Primary Outcome Measure Information:
Title
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337
Description
Trough FEV1 is defined as the FEV1 measured at the -10 min time point at the end of the dosing interval (24 h post drug administration).
Time Frame
Baseline and Day 337
Title
Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Description
Time to first COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation.
Time Frame
During actual study treatment period (planned Day 1 to Day 337)
Secondary Outcome Measure Information:
Title
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29
Description
Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.
Time Frame
Baseline and Day 29
Title
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 169
Description
Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.
Time Frame
Baseline and Day 169
Title
Number of COPD Exacerbations Per Patient - Exposure Adjusted
Description
Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. number of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)
Time Frame
During actual study treatment period (planned Day 1 to Day 337)
Title
Number of COPD Exacerbations Per Patient - naïve Estimate
Description
Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)
Time Frame
During actual study treatment period (planned Day 1 to Day 337)
Title
Number of Patients With at Least One COPD Exacerbation
Description
Number of patients with at least one COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)
Time Frame
During actual study treatment period (planned Day 1 to Day 337)
Title
Time to First Hospitalisation for COPD Exacerbation
Description
Time to first hospitalisation for COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation
Time Frame
During actual study treatment period (planned Day 1 to Day 337)
Title
Number of Hospitalisations for COPD Exacerbations Per Patient - Exposure Adjusted
Description
Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. no. of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)
Time Frame
During actual study treatment period (planned Day 1 to Day 337)
Title
Number of Hospitalisations for COPD Exacerbations Per Patient - naïve Estimate
Description
Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)
Time Frame
During actual study treatment period (planned Day 1 to Day 337)
Title
Number of Patients With at Least One Hospitalisation for a COPD Exacerbation
Description
Number of patients with at least one hospitalisation for a COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)
Time Frame
During actual study treatment period (planned Day 1 to Day 337)
Title
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 337
Description
The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Time Frame
Baseline and Day 337
Title
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 169
Description
The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Time Frame
Baseline and Day 169
Title
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 337
Description
The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Time Frame
Baseline and Day 337
Title
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 169
Description
The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state
Time Frame
Baseline and Day 169
Title
Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 29
Description
Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.
Time Frame
Baseline and Day 29
Title
Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 169
Description
Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.
Time Frame
Baseline and Day 169
Title
Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 337
Description
Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.
Time Frame
Baseline and Day 337
Title
Marked Changes From Baseline in Vital Signs at End of Treatment
Description
Marked changes from baseline in vital signs (diastolic and systolic blood pressure (DBP and SBP) and pulse rate (PR)) at end of treatment. SBP - Increase means SBP >150 mmHg and an increase above baseline of >25 mmHg. SBP - Decrease means SBP <100 mmHg and a decrease below baseline of >10 mmHg. DBP - Increase means DBP >90 mmHg and an increase above baseline of >10 mmHg. DBP - Decrease means DBP <60 mmHg and a decrease below baseline of >10 mmHg. PR - Increase means PR >100 bpm and an increase above baseline of >10 bpm. PR - Decrease means PR <60 bpm and a decrease below baseline of >10 bpm.
Time Frame
Baseline and end of treatment
Title
Clinically Relevant Findings in Physical Examination and ECG
Description
Clinically relevant findings in Physical Examination and ECG at end of treatment
Time Frame
End of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female At least 40 years old Smoker or ex-smoker Smoking history > 10 pack-years Forced Expiratory Volume in 1 Second (FEV1) < 60% predicted Exclusion Criteria: Recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure History of asthma or allergic conditions. Malignancy requiring treatment within past 5 years Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis Known active tuberculosis Known hypersensitivity to anticholinergic drugs.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
205.372.01012 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
205.372.01020 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
205.372.01062 Boehringer Ingelheim Investigational Site
City
Mobile
State/Province
Alabama
Country
United States
Facility Name
205.372.01048 Boehringer Ingelheim Investigational Site
City
Berkeley
State/Province
California
Country
United States
Facility Name
205.372.01037 Boehringer Ingelheim Investigational Site
City
Huntington Park
State/Province
California
Country
United States
Facility Name
205.372.01058 Boehringer Ingelheim Investigational Site
City
Long Beach
State/Province
California
Country
United States
Facility Name
205.372.01059 Boehringer Ingelheim Investigational Site
City
Long Beach
State/Province
California
Country
United States
Facility Name
205.372.01007 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
205.372.01034 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
205.372.01028 Boehringer Ingelheim Investigational Site
City
Rancho Mirage
State/Province
California
Country
United States
Facility Name
205.372.01011 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
205.372.01066 Boehringer Ingelheim Investigational Site
City
Boulder
State/Province
Colorado
Country
United States
Facility Name
205.372.01008 Boehringer Ingelheim Investigational Site
City
Norwalk
State/Province
Connecticut
Country
United States
Facility Name
205.372.01004 Boehringer Ingelheim Investigational Site
City
Brandon
State/Province
Florida
Country
United States
Facility Name
205.372.01060 Boehringer Ingelheim Investigational Site
City
Clearwater
State/Province
Florida
Country
United States
Facility Name
205.372.01069 Boehringer Ingelheim Investigational Site
City
Miami Beach
State/Province
Florida
Country
United States
Facility Name
205.372.01023 Boehringer Ingelheim Investigational Site
City
West Palm Beach
State/Province
Florida
Country
United States
Facility Name
205.372.01053 Boehringer Ingelheim Investigational Site
City
Winter Park
State/Province
Florida
Country
United States
Facility Name
205.372.01045 Boehringer Ingelheim Investigational Site
City
Calhoun
State/Province
Georgia
Country
United States
Facility Name
205.372.01043 Boehringer Ingelheim Investigational Site
City
Normal
State/Province
Illinois
Country
United States
Facility Name
205.372.01061 Boehringer Ingelheim Investigational Site
City
Dubuque
State/Province
Iowa
Country
United States
Facility Name
205.372.01035 Boehringer Ingelheim Investigational Site
City
Wichita
State/Province
Kansas
Country
United States
Facility Name
205.372.01049 Boehringer Ingelheim Investigational Site
City
Shreveport
State/Province
Louisiana
Country
United States
Facility Name
205.372.01015 Boehringer Ingelheim Investigational Site
City
Biddeford
State/Province
Maine
Country
United States
Facility Name
205.372.01067 Boehringer Ingelheim Investigational Site
City
Columbia
State/Province
Maryland
Country
United States
Facility Name
205.372.01006 Boehringer Ingelheim Investigational Site
City
Rockville
State/Province
Maryland
Country
United States
Facility Name
205.372.01013 Boehringer Ingelheim Investigational Site
City
Detroit
State/Province
Michigan
Country
United States
Facility Name
205.372.01003 Boehringer Ingelheim Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
205.372.01021 Boehringer Ingelheim Investigational Site
City
Chesterfield
State/Province
Missouri
Country
United States
Facility Name
205.372.01014 Boehringer Ingelheim Investigational Site
City
St. Louis
State/Province
Missouri
Country
United States
Facility Name
205.372.01036 Boehringer Ingelheim Investigational Site
City
Omaha
State/Province
Nebraska
Country
United States
Facility Name
205.372.01046 Boehringer Ingelheim Investigational Site
City
Albuquerque
State/Province
New Mexico
Country
United States
Facility Name
205.372.01024 Boehringer Ingelheim Investigational Site
City
Mineola
State/Province
New York
Country
United States
Facility Name
205.372.01029 Boehringer Ingelheim Investigational Site
City
Rochester
State/Province
New York
Country
United States
Facility Name
205.372.01030 Boehringer Ingelheim Investigational Site
City
Syracuse
State/Province
New York
Country
United States
Facility Name
205.372.01026 Boehringer Ingelheim Investigational Site
City
Chapel Hill
State/Province
North Carolina
Country
United States
Facility Name
205.372.01019 Boehringer Ingelheim Investigational Site
City
Charlotte
State/Province
North Carolina
Country
United States
Facility Name
205.372.01027 Boehringer Ingelheim Investigational Site
City
Elizabeth City
State/Province
North Carolina
Country
United States
Facility Name
205.372.01038 Boehringer Ingelheim Investigational Site
City
Raleigh
State/Province
North Carolina
Country
United States
Facility Name
205.372.01031 Boehringer Ingelheim Investigational Site
City
Winston-Salem
State/Province
North Carolina
Country
United States
Facility Name
205.372.01017 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
205.372.01041 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
205.372.01044 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
205.372.01001 Boehringer Ingelheim Investigational Site
City
Oklahoma City
State/Province
Oklahoma
Country
United States
Facility Name
205.372.01063 Boehringer Ingelheim Investigational Site
City
Eugene
State/Province
Oregon
Country
United States
Facility Name
205.372.01068 Boehringer Ingelheim Investigational Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
205.372.01056 Boehringer Ingelheim Investigational Site
City
Swathmore
State/Province
Pennsylvania
Country
United States
Facility Name
205.372.01039 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
205.372.01050 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
205.372.01005 Boehringer Ingelheim Investigational Site
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
205.372.01018 Boehringer Ingelheim Investigational Site
City
Killeen
State/Province
Texas
Country
United States
Facility Name
205.372.01040 Boehringer Ingelheim Investigational Site
City
New Braunfels
State/Province
Texas
Country
United States
Facility Name
205.372.01052 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
205.372.01022 Boehringer Ingelheim Investigational Site
City
Danville
State/Province
Virginia
Country
United States
Facility Name
205.372.01065 Boehringer Ingelheim Investigational Site
City
Lynchburg
State/Province
Virginia
Country
United States
Facility Name
205.372.01055 Boehringer Ingelheim Investigational Site
City
Richmond
State/Province
Virginia
Country
United States
Facility Name
205.372.01064 Boehringer Ingelheim Investigational Site
City
Tacoma
State/Province
Washington
Country
United States
Facility Name
205.372.61002 Woolcock Institute of Medical Research
City
Glebe
State/Province
New South Wales
Country
Australia
Facility Name
205.372.61009 Thoracic & General Physician
City
Cairns
State/Province
Queensland
Country
Australia
Facility Name
205.372.61005 Redcliffe Hospital
City
Redcliffe
State/Province
Queensland
Country
Australia
Facility Name
205.372.61006 The Investigator Clinic
City
Port Lincoln
State/Province
South Australia
Country
Australia
Facility Name
205.372.61007 The Burnside War Memorial Hospital
City
Toorak Gardens
State/Province
South Australia
Country
Australia
Facility Name
205.372.61004 Boehringer Ingelheim Investigational Site
City
Woodville
State/Province
South Australia
Country
Australia
Facility Name
205.372.61010 Ecru
City
Box Hill
State/Province
Victoria
Country
Australia
Facility Name
205.372.61008 Geelong Clinical Research Centre
City
Geelong
State/Province
Victoria
Country
Australia
Facility Name
205.372.61001 Emeritus Research
City
Malvern
State/Province
Victoria
Country
Australia
Facility Name
205.372.61003 Sir Charles Gairdner Hospital
City
Nedlands
State/Province
Western Australia
Country
Australia
Facility Name
205.372.55012 Universidade Federal de Santa Catarina
City
Florianópolis
Country
Brazil
Facility Name
205.372.55009 Hospital das Clínicas de Goiânia
City
Goiânia
Country
Brazil
Facility Name
205.372.55005 Hospital Geral Otávio de Freitas
City
Recife
Country
Brazil
Facility Name
205.372.55001 INCOR e Hospital das Clínicas da Universidade de São Paulo
City
São Paulo - SP
Country
Brazil
Facility Name
205.372.55010 Unidade de Coracao e Pulmao do Dto. de Medicina
City
São Paulo - SP
Country
Brazil
Facility Name
205.372.55011 CEDOES - Diagnóstico e Pesquisa
City
Vitória
Country
Brazil
Facility Name
205.372.11007 Heritage Medical Research Building
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
205.372.11013 Calgary West Medical Centre
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
205.372.11011 Hermitage Medicentre
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
205.372.11017 Boehringer Ingelheim Investigational Site
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
205.372.11020 Wetaskiwin Lung Laboratory
City
Wetaskiwin
State/Province
Alberta
Country
Canada
Facility Name
205.372.11010 Dr. Kay Ho
City
Chilliwack
State/Province
British Columbia
Country
Canada
Facility Name
205.372.11018 Pacific Lung Health Centre
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
205.372.11005 Professional Corp. Respirology
City
Saint John
State/Province
New Brunswick
Country
Canada
Facility Name
205.372.11009 White Hills Medical Clinic
City
St. John's
State/Province
Newfoundland and Labrador
Country
Canada
Facility Name
205.372.11012 West Lincoln Memorial Hospital
City
Grimsby
State/Province
Ontario
Country
Canada
Facility Name
205.372.11014 Dr. Robert Luton
City
London
State/Province
Ontario
Country
Canada
Facility Name
205.372.11001 Niagara Clinical Research
City
Niagara Falls
State/Province
Ontario
Country
Canada
Facility Name
205.372.11019 Allergy and Asthma Research Centre
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
205.372.11003 London Road Diagnostic Clinic and Medical Centre
City
Sarnia
State/Province
Ontario
Country
Canada
Facility Name
205.372.11016 London Road Diagnostic Clinic and Medical Centre
City
Sarnia
State/Province
Ontario
Country
Canada
Facility Name
205.372.11002 Centenary Respiratory Research Associates
City
Scarborough
State/Province
Ontario
Country
Canada
Facility Name
205.372.11006 Clinique de médecine familiale de La Malbaie
City
La Malbaie
State/Province
Quebec
Country
Canada
Facility Name
205.372.11004 Mount Royal Family Physicians
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
205.372.11015 Dr. Arun Nayar
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
205.372.86002 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
205.372.86003 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
205.372.86004 Boehringer Ingelheim Investigational Site
City
Beijing
Country
China
Facility Name
205.372.86009 Boehringer Ingelheim Investigational Site
City
Chengdu, Sichuan Province
Country
China
Facility Name
205.372.86008 Boehringer Ingelheim Investigational Site
City
Chongqing
Country
China
Facility Name
205.372.86001 Boehringer Ingelheim Investigational Site
City
Guangzhou
Country
China
Facility Name
205.372.86010 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
205.372.86011 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
205.372.86012 Boehringer Ingelheim Investigational Site
City
Shanghai
Country
China
Facility Name
205.372.86005 Boehringer Ingelheim Investigational Site
City
Shenyang
Country
China
Facility Name
205.372.86006 Boehringer Ingelheim Investigational Site
City
Shenyang
Country
China
Facility Name
205.372.86007 Boehringer Ingelheim Investigational Site
City
Wuhan
Country
China
Facility Name
205.372.45004 Boehringer Ingelheim Investigational Site
City
Aarhus C
Country
Denmark
Facility Name
205.372.45005 Boehringer Ingelheim Investigational Site
City
Horsens
Country
Denmark
Facility Name
205.372.45002 Boehringer Ingelheim Investigational Site
City
Hvidovre
Country
Denmark
Facility Name
205.372.45001 Boehringer Ingelheim Investigational Site
City
København NV
Country
Denmark
Facility Name
205.372.45003 Boehringer Ingelheim Investigational Site
City
Odense C
Country
Denmark
Facility Name
205.372.45006 Boehringer Ingelheim Investigational Site
City
Silkeborg
Country
Denmark
Facility Name
205.372.35804 Boehringer Ingelheim Investigational Site
City
Helsinki
Country
Finland
Facility Name
205.372.35802 Boehringer Ingelheim Investigational Site
City
Jyväskylä
Country
Finland
Facility Name
205.372.35803 Boehringer Ingelheim Investigational Site
City
Lahti
Country
Finland
Facility Name
205.372.35801 Boehringer Ingelheim Investigational Site
City
Tampere
Country
Finland
Facility Name
205.372.3318A Clinique du Parc
City
Castelnau le Lez
Country
France
Facility Name
205.372.3318B Clinique du Parc
City
Castelnau le Lez
Country
France
Facility Name
205.372.3304A Cabinet Médical
City
Chamalières
Country
France
Facility Name
205.372.3301A Hôpital Gabriel Montpied
City
Clermont Ferrand cedex 1
Country
France
Facility Name
205.372.3310A Centre Hospitalier
City
Denain
Country
France
Facility Name
205.372.3314A Cabinet Médical
City
Grasse
Country
France
Facility Name
205.372.3306A Hôpital Ambroise Paré
City
Marseille
Country
France
Facility Name
205.372.3303A Hôpital Notre Dame de Bon Secours
City
Metz cedex 1
Country
France
Facility Name
205.372.3303B Hôpital Notre Dame de Bon Secours
City
Metz cedex 1
Country
France
Facility Name
205.372.3312A Cabinet Médical
City
Montigny les Metz
Country
France
Facility Name
205.372.3312B Cabinet Médical
City
Montigny les Metz
Country
France
Facility Name
205.372.3302A Centre Médical Erdre Saint Augustin
City
Nantes
Country
France
Facility Name
205.372.3305A Cabinet Médical
City
Nice
Country
France
Facility Name
205.372.3305B Cabinet Médical
City
Nice
Country
France
Facility Name
205.372.3315B Hôpital Caremeau
City
Nimes cedex 9
Country
France
Facility Name
205.372.3315A Hôpital Caremeau
City
Nîmes
Country
France
Facility Name
205.372.3317A Cabinet de Pneumologie
City
Nîmes
Country
France
Facility Name
205.372.3320A Polyclinique Les Fleurs
City
Ollioules
Country
France
Facility Name
205.372.3320B Polyclinique Les Fleurs
City
Ollioules
Country
France
Facility Name
205.372.3316A Clinique les Bleuets
City
Reims
Country
France
Facility Name
205.372.3316B Clinique les Bleuets
City
Reims
Country
France
Facility Name
205.372.3319A Institut Arnault Tzanck
City
Saint Laurent du Var
Country
France
Facility Name
205.372.3325A Cabinet Médical
City
Six Four les Plages
Country
France
Facility Name
205.372.3321A Centre Hospitalier
City
St Gaudens
Country
France
Facility Name
205.372.3321C Centre Hospitalier
City
St Gaudens
Country
France
Facility Name
205.372.3324A Cabinet Médical
City
Toulon
Country
France
Facility Name
205.372.3309A Cabinet médical
City
Toulouse
Country
France
Facility Name
205.372.3309B Cabinet médical
City
Toulouse
Country
France
Facility Name
205.372.49002 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
205.372.49004 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
205.372.49013 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
205.372.49007 Boehringer Ingelheim Investigational Site
City
Bonn
Country
Germany
Facility Name
205.372.49008 Boehringer Ingelheim Investigational Site
City
Bruchsal
Country
Germany
Facility Name
205.372.49011 Boehringer Ingelheim Investigational Site
City
Frankfurt/Main
Country
Germany
Facility Name
205.372.49012 Boehringer Ingelheim Investigational Site
City
Gelnhausen
Country
Germany
Facility Name
205.372.49006 Boehringer Ingelheim Investigational Site
City
Gütersloh
Country
Germany
Facility Name
205.372.49014 Boehringer Ingelheim Investigational Site
City
Hannover
Country
Germany
Facility Name
205.372.49005 Boehringer Ingelheim Investigational Site
City
Kassel
Country
Germany
Facility Name
205.372.49009 Boehringer Ingelheim Investigational Site
City
Minden
Country
Germany
Facility Name
205.372.49010 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
205.372.49016 Boehringer Ingelheim Investigational Site
City
Weinheim
Country
Germany
Facility Name
205.372.49015 Boehringer Ingelheim Investigational Site
City
Weyhe
Country
Germany
Facility Name
205.372.49001 Boehringer Ingelheim Investigational Site
City
Wiesloch
Country
Germany
Facility Name
205.372.49003 Boehringer Ingelheim Investigational Site
City
Witten
Country
Germany
Facility Name
205.372.30001 Boehringer Ingelheim Investigational Site
City
Athens
Country
Greece
Facility Name
205.372.30002 Boehringer Ingelheim Investigational Site
City
Athens
Country
Greece
Facility Name
205.372.30003 Boehringer Ingelheim Investigational Site
City
Athens
Country
Greece
Facility Name
205.372.30013 Boehringer Ingelheim Investigational Site
City
Athens
Country
Greece
Facility Name
205.372.30015 Boehringer Ingelheim Investigational Site
City
Athens
Country
Greece
Facility Name
205.372.30009 Boehringer Ingelheim Investigational Site
City
Heraklion-Crete
Country
Greece
Facility Name
205.372.30007 Boehringer Ingelheim Investigational Site
City
Kalamaria
Country
Greece
Facility Name
205.372.30005 Boehringer Ingelheim Investigational Site
City
Kavala
Country
Greece
Facility Name
205.372.30004 Boehringer Ingelheim Investigational Site
City
Komotini
Country
Greece
Facility Name
205.372.30011 Boehringer Ingelheim Investigational Site
City
Korinthos
Country
Greece
Facility Name
205.372.30019 Boehringer Ingelheim Investigational Site
City
Nafplio
Country
Greece
Facility Name
205.372.30008 Boehringer Ingelheim Investigational Site
City
Serres
Country
Greece
Facility Name
205.372.30006 Boehringer Ingelheim Investigational Site
City
Thessaloniki
Country
Greece
Facility Name
205.372.30017 Boehringer Ingelheim Investigational Site
City
Thessaloniki
Country
Greece
Facility Name
205.372.30014 Boehringer Ingelheim Investigational Site
City
Thiva
Country
Greece
Facility Name
205.372.85203 Boehringer Ingelheim Investigational Site
City
Hong Kong
Country
Hong Kong
Facility Name
205.372.85201 Boehringer Ingelheim Investigational Site
City
Kowloon
Country
Hong Kong
Facility Name
205.372.36001 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
205.372.36002 Boehringer Ingelheim Investigational Site
City
Debrecen
Country
Hungary
Facility Name
205.372.36004 Boehringer Ingelheim Investigational Site
City
Deszk
Country
Hungary
Facility Name
205.372.36005 Boehringer Ingelheim Investigational Site
City
Erd
Country
Hungary
Facility Name
205.372.36006 Boehringer Ingelheim Investigational Site
City
Mosonmagyarovar
Country
Hungary
Facility Name
205.372.36007 Boehringer Ingelheim Investigational Site
City
Sopron
Country
Hungary
Facility Name
205.372.91005 Boehringer Ingelheim Investigational Site
City
Andhra Pradesh
Country
India
Facility Name
205.372.91016 Boehringer Ingelheim Investigational Site
City
Andhra Pradesh
Country
India
Facility Name
205.372.91003 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
205.372.91006 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
205.372.91017 Boehringer Ingelheim Investigational Site
City
Calicut,Kerala
Country
India
Facility Name
205.372.91007 Boehringer Ingelheim Investigational Site
City
Chennai
Country
India
Facility Name
205.372.91010 Boehringer Ingelheim Investigational Site
City
Chennai
Country
India
Facility Name
205.372.91002 Boehringer Ingelheim Investigational Site
City
Coimbatore
Country
India
Facility Name
205.372.91009 Boehringer Ingelheim Investigational Site
City
Gujarat
Country
India
Facility Name
205.372.91011 Boehringer Ingelheim Investigational Site
City
indore,MP
Country
India
Facility Name
205.372.91012 Boehringer Ingelheim Investigational Site
City
Maharashtra
Country
India
Facility Name
205.372.91004 Boehringer Ingelheim Investigational Site
City
Mumbai
Country
India
Facility Name
205.372.91008 Boehringer Ingelheim Investigational Site
City
Mumbai
Country
India
Facility Name
205.372.91015 Boehringer Ingelheim Investigational Site
City
New Delhi
Country
India
Facility Name
205.372.91014 Boehringer Ingelheim Investigational Site
City
Punjab
Country
India
Facility Name
205.372.91013 Boehringer Ingelheim Investigational Site
City
Tamil Nadu
Country
India
Facility Name
205.372.91001 Boehringer Ingelheim Investigational Site
City
Uttar Pradesh
Country
India
Facility Name
205.372.35303 Boehringer Ingelheim Investigational Site
City
Mullingar
Country
Ireland
Facility Name
205.372.39007 Boehringer Ingelheim Investigational Site
City
Bussolengo (vr)
Country
Italy
Facility Name
205.372.39012 Boehringer Ingelheim Investigational Site
City
Ferrara
Country
Italy
Facility Name
205.372.39003 Boehringer Ingelheim Investigational Site
City
Genova
Country
Italy
Facility Name
205.372.39004 Boehringer Ingelheim Investigational Site
City
Genova
Country
Italy
Facility Name
205.372.39005 Boehringer Ingelheim Investigational Site
City
Milano
Country
Italy
Facility Name
205.372.39008 Boehringer Ingelheim Investigational Site
City
Modena
Country
Italy
Facility Name
205.372.39009 Boehringer Ingelheim Investigational Site
City
Orbassano (to)
Country
Italy
Facility Name
205.372.39001 Boehringer Ingelheim Investigational Site
City
Pisa
Country
Italy
Facility Name
205.372.39010 Boehringer Ingelheim Investigational Site
City
Pordenone
Country
Italy
Facility Name
205.372.39002 Boehringer Ingelheim Investigational Site
City
Prato (fi)
Country
Italy
Facility Name
205.372.39011 Boehringer Ingelheim Investigational Site
City
Roma
Country
Italy
Facility Name
205.372.39006 Boehringer Ingelheim Investigational Site
City
Trieste
Country
Italy
Facility Name
205.372.82010 Boehringer Ingelheim Investigational Site
City
Anyang
Country
Korea, Republic of
Facility Name
205.372.82005 Boehringer Ingelheim Investigational Site
City
Daegu
Country
Korea, Republic of
Facility Name
205.372.82009 Boehringer Ingelheim Investigational Site
City
Daejoen
Country
Korea, Republic of
Facility Name
205.372.82003 Boehringer Ingelheim Investigational Site
City
Incheon
Country
Korea, Republic of
Facility Name
205.372.82008 Boehringer Ingelheim Investigational Site
City
Jeonbuk
Country
Korea, Republic of
Facility Name
205.372.82007 Boehringer Ingelheim Investigational Site
City
Kwangju
Country
Korea, Republic of
Facility Name
205.372.82002 Boehringer Ingelheim Investigational Site
City
Pusan
Country
Korea, Republic of
Facility Name
205.372.82001 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
205.372.82004 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
205.372.82006 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
205.372.37001 Boehringer Ingelheim Investigational Site
City
Kaunas
Country
Lithuania
Facility Name
205.372.37003 Boehringer Ingelheim Investigational Site
City
Kaunas
Country
Lithuania
Facility Name
205.372.37002 Boehringer Ingelheim Investigational Site
City
Vilnius
Country
Lithuania
Facility Name
205.372.60007 Boehringer Ingelheim Investigational Site
City
Johor Baharu
Country
Malaysia
Facility Name
205.372.60004 Boehringer Ingelheim Investigational Site
City
Kelantan Darul Naim
Country
Malaysia
Facility Name
205.372.60005 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
205.372.60006 Boehringer Ingelheim Investigational Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
205.372.60002 Boehringer Ingelheim Investigational Site
City
Kuching, Sarawak
Country
Malaysia
Facility Name
205.372.60003 Boehringer Ingelheim Investigational Site
City
Penang
Country
Malaysia
Facility Name
205.372.60001 Boehringer Ingelheim Investigational Site
City
Selangor
Country
Malaysia
Facility Name
205.372.52018 Hospital Universitario de Chihuahua
City
Chihuahua
Country
Mexico
Facility Name
205.372.52017 Instituto Nacional de Enfermedades Respiratorias (INER)
City
Col. Seccion XVI
Country
Mexico
Facility Name
205.372.52013 Sanatorio Henri Dunant
City
Cuernavaca, Mor. México
Country
Mexico
Facility Name
205.372.52009 Hospital Civil Antiguo
City
Guadalajara Jal.
Country
Mexico
Facility Name
205.372.52005 Hospital Civil Nuevo de Guadalajara
City
Guadalajara
Country
Mexico
Facility Name
205.372.52001 Hospital General del Estado de Sonora
City
Hermosillo, Sonora
Country
Mexico
Facility Name
205.372.52014 Hospital Angeles de las Lomas
City
Huixquilucan Edo.Mex.
Country
Mexico
Facility Name
205.372.52004 Clínica de Mérida
City
Merida Yuc.
Country
Mexico
Facility Name
205.372.52016 Hospital General de Mexicali
City
Mexicali Baja California Norte
Country
Mexico
Facility Name
205.372.52002 Unidad de Investigación clínica en Medicina
City
Monterrey, Nuevo León
Country
Mexico
Facility Name
205.372.52006 Hospital Universitario
City
Monterrey, Nuevo León
Country
Mexico
Facility Name
205.372.52010 Hospital General Agustin O´Haran
City
Mérida Yucatán
Country
Mexico
Facility Name
205.372.52012 Hospital de Nuestra Señora de la Salud
City
San Luis Potosi
Country
Mexico
Facility Name
205.372.52003 Hospital "Angel Leaño"
City
Zapopan, Jal.
Country
Mexico
Facility Name
205.372.31009 Boehringer Ingelheim Investigational Site
City
Amsterdam
Country
Netherlands
Facility Name
205.372.31006 Boehringer Ingelheim Investigational Site
City
Drachten
Country
Netherlands
Facility Name
205.372.31001 Boehringer Ingelheim Investigational Site
City
Groningen
Country
Netherlands
Facility Name
205.372.31011 Boehringer Ingelheim Investigational Site
City
Hoofddorp
Country
Netherlands
Facility Name
205.372.31007 Boehringer Ingelheim Investigational Site
City
Leeuwarden
Country
Netherlands
Facility Name
205.372.31004 Boehringer Ingelheim Investigational Site
City
Roosendaal
Country
Netherlands
Facility Name
205.372.31003 Boehringer Ingelheim Investigational Site
City
Sneek
Country
Netherlands
Facility Name
205.372.31012 Boehringer Ingelheim Investigational Site
City
Utrecht
Country
Netherlands
Facility Name
205.372.31002 Boehringer Ingelheim Investigational Site
City
Voorburg
Country
Netherlands
Facility Name
205.372.31008 Boehringer Ingelheim Investigational Site
City
Weerselo
Country
Netherlands
Facility Name
205.372.31005 Boehringer Ingelheim Investigational Site
City
Winschoten
Country
Netherlands
Facility Name
205.372.47001 Boehringer Ingelheim Investigational Site
City
Sandvika
Country
Norway
Facility Name
205.372.47003 Boehringer Ingelheim Investigational Site
City
Trondheim
Country
Norway
Facility Name
205.372.47002 Boehringer Ingelheim Investigational Site
City
Ålesund
Country
Norway
Facility Name
205.372.35102 Hospital Fernando Fonseca
City
Amadora
Country
Portugal
Facility Name
205.372.35101 Hospital Pulido Valente
City
Lisboa
Country
Portugal
Facility Name
205.372.35104 Hospital de Santa Marta
City
Lisboa
Country
Portugal
Facility Name
205.372.35103 Hospital de São João
City
Porto
Country
Portugal
Facility Name
205.372.35105 Centro Hospitalar do Alto Minho, Estrada de Santa Luzia
City
Viana do Castelo
Country
Portugal
Facility Name
205.372.65001 Boehringer Ingelheim Investigational Site
City
Singapore
Country
Singapore
Facility Name
205.372.65003 Boehringer Ingelheim Investigational Site
City
Singapore
Country
Singapore
Facility Name
205.372.65005 Boehringer Ingelheim Investigational Site
City
Singapore
Country
Singapore
Facility Name
205.372.42102 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
205.372.42103 Boehringer Ingelheim Investigational Site
City
Nove Zamky
Country
Slovakia
Facility Name
205.372.27002 Boehringer Ingelheim Investigational Site
City
Bellville
Country
South Africa
Facility Name
205.372.27001 Boehringer Ingelheim Investigational Site
City
Cape Town
Country
South Africa
Facility Name
205.372.27004 Boehringer Ingelheim Investigational Site
City
Cape Town
Country
South Africa
Facility Name
205.372.27008 Boehringer Ingelheim Investigational Site
City
Cape Town
Country
South Africa
Facility Name
205.372.27006 Boehringer Ingelheim Investigational Site
City
Centurion
Country
South Africa
Facility Name
205.372.27003 Boehringer Ingelheim Investigational Site
City
Durban
Country
South Africa
Facility Name
205.372.27005 Boehringer Ingelheim Investigational Site
City
Pretoria
Country
South Africa
Facility Name
205.372.27007 Boehringer Ingelheim Investigational Site
City
Somerset West
Country
South Africa
Facility Name
205.372.34005 Hospital San Pedro de Alcántara
City
Cáceres
Country
Spain
Facility Name
205.372.34004 Hospital Gregorio Marañón
City
Madrid
Country
Spain
Facility Name
205.372.34006 Hospital 12 de octubre
City
Madrid
Country
Spain
Facility Name
205.372.34001 Hospital Mutua Terrassa
City
Terrassa (Barcelona)
Country
Spain
Facility Name
205.372.34002 Hospital Universitario Dr. Peset
City
Valencia
Country
Spain
Facility Name
205.372.46001 Björknäs Vårdcentral
City
Boden
Country
Sweden
Facility Name
205.372.46004 Näsets läkargrupp
City
Höllviken
Country
Sweden
Facility Name
205.372.46005 Lungmedicinska kliniken
City
Linköping
Country
Sweden
Facility Name
205.372.46006 Lungmedicinska Kliniken
City
Stockholm
Country
Sweden
Facility Name
205.372.46002 Alnö Vårdcentral
City
Sundsvall
Country
Sweden
Facility Name
205.372.41002 Boehringer Ingelheim Investigational Site
City
Lugano
Country
Switzerland
Facility Name
205.372.41003 Boehringer Ingelheim Investigational Site
City
Montana
Country
Switzerland
Facility Name
205.372.41001 Boehringer Ingelheim Investigational Site
City
Zürich
Country
Switzerland
Facility Name
205.372.88607 Kaohsiung Medical University Hospital
City
Kaohsiung
Country
Taiwan
Facility Name
205.372.88606 National Cheng Kung University Hospital
City
Tainan
Country
Taiwan
Facility Name
205.372.88601 National Taiwan University Hospital
City
Taipei
Country
Taiwan
Facility Name
205.372.88602 Taipei Veterans General Hospital
City
Taipei
Country
Taiwan
Facility Name
205.372.88603 Mackay Memorial Hospital
City
Taipei
Country
Taiwan
Facility Name
205.372.88604 Tri-Service General Hospital
City
Taipei
Country
Taiwan
Facility Name
205.372.88608 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
205.372.88609 Boehringer Ingelheim Investigational Site
City
Taipei
Country
Taiwan
Facility Name
205.372.88605 Chang Gung Memorial Hosp-Linkou
City
Taoyuan
Country
Taiwan
Facility Name
205.372.90006 Gazi Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.
City
Ankara
Country
Turkey
Facility Name
205.372.90007 Atatürk Gög. Hastaliklari ve Cerrahisi Egitim Hastanesi
City
Ankara
Country
Turkey
Facility Name
205.372.90003 Uludag Universitesi Tip Fakultesi Gogus Hastaliklari
City
Bursa
Country
Turkey
Facility Name
205.372.90009 Trakya Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.
City
Edirne
Country
Turkey
Facility Name
205.372.90004 Dr. Lütfi Kirdar Egitim ve Arastirma Hastanesi
City
Istanbul
Country
Turkey
Facility Name
205.372.90005 Istanbul Universitesi Cerrahpasa Tip Fakultesi
City
Istanbul
Country
Turkey
Facility Name
205.372.90001 Izmir Tepecik Gogus Hastaliklari ve Gogus Cerrahisi Hast.
City
Izmir
Country
Turkey
Facility Name
205.372.90008 Erciyes Universitesi Tip Fakultesi
City
Kayseri
Country
Turkey
Facility Name
205.372.90010 Selcuk Universitesi Tip Fakultesi
City
Konya
Country
Turkey
Facility Name
205.372.90002 19 Mayis Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D
City
Samsun
Country
Turkey
Facility Name
205.372.44027 Boehringer Ingelheim Investigational Site
City
Aston Clinton, Aylesbury
Country
United Kingdom
Facility Name
205.372.44022 Boehringer Ingelheim Investigational Site
City
Carmarthen
Country
United Kingdom
Facility Name
205.372.44002 Boehringer Ingelheim Investigational Site
City
Chertsey
Country
United Kingdom
Facility Name
205.372.44023 Boehringer Ingelheim Investigational Site
City
Chesterfield
Country
United Kingdom
Facility Name
205.372.44014 Boehringer Ingelheim Investigational Site
City
Darlington
Country
United Kingdom
Facility Name
205.372.44009 Boehringer Ingelheim Investigational Site
City
East Horsley
Country
United Kingdom
Facility Name
205.372.44011 Boehringer Ingelheim Investigational Site
City
Fowey
Country
United Kingdom
Facility Name
205.372.44003 Boehringer Ingelheim Investigational Site
City
Frome
Country
United Kingdom
Facility Name
205.372.44026 Boehringer Ingelheim Investigational Site
City
Greenisland
Country
United Kingdom
Facility Name
205.372.44013 Boehringer Ingelheim Investigational Site
City
Heywood
Country
United Kingdom
Facility Name
205.372.44016 Boehringer Ingelheim Investigational Site
City
Isleworth
Country
United Kingdom
Facility Name
205.372.44020 Boehringer Ingelheim Investigational Site
City
Kirkby in Ashfield
Country
United Kingdom
Facility Name
205.372.44024 Boehringer Ingelheim Investigational Site
City
Mortimer
Country
United Kingdom
Facility Name
205.372.44001 Boehringer Ingelheim Investigational Site
City
Nottingham
Country
United Kingdom
Facility Name
205.372.44018 Boehringer Ingelheim Investigational Site
City
Penzance
Country
United Kingdom
Facility Name
205.372.44021 Boehringer Ingelheim Investigational Site
City
Plymouth
Country
United Kingdom
Facility Name
205.372.44007 Boehringer Ingelheim Investigational Site
City
Sheffield
Country
United Kingdom
Facility Name
205.372.44010 Boehringer Ingelheim Investigational Site
City
Sneinton, Nottingham
Country
United Kingdom
Facility Name
205.372.44005 Boehringer Ingelheim Investigational Site
City
St Just, Penzance
Country
United Kingdom
Facility Name
205.372.44015 Boehringer Ingelheim Investigational Site
City
St. Austell
Country
United Kingdom
Facility Name
205.372.44006 Boehringer Ingelheim Investigational Site
City
Sunderland
Country
United Kingdom
Facility Name
205.372.44008 Boehringer Ingelheim Investigational Site
City
Wellingborough
Country
United Kingdom
Facility Name
205.372.44012 Boehringer Ingelheim Investigational Site
City
Westbury on Trym
Country
United Kingdom
Facility Name
205.372.44028 Boehringer Ingelheim Investigational Site
City
Windsor
Country
United Kingdom
Facility Name
205.372.44019 Boehringer Ingelheim Investigational Site
City
Woking
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
32943047
Citation
Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, Miravitlles M, Chalmers JD, Calverley PMA. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020 Sep 17;21(1):240. doi: 10.1186/s12931-020-01482-1.
Results Reference
derived
PubMed Identifier
20620037
Citation
Bateman ED, Tashkin D, Siafakas N, Dahl R, Towse L, Massey D, Pavia D, Zhong NS. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010 Oct;104(10):1460-72. doi: 10.1016/j.rmed.2010.06.004.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.372_U09-1128-01-DS.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/Pooled%20analysis/PA_205.372_251_252_254_255_U10-3255-01.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.372_literature.pdf
Description
Related Info

Learn more about this trial

Tiotropium / Respimat One Year Study in COPD.

We'll reach out to this number within 24 hrs